Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942317 | 0.86 | CYP1A1 (0.34) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL435367 | 0.83 | GAA (0.33) | DYRK1ACLK4GAANOTUMCCNB2 | |
| SCHEMBL2951402 | 0.80 | PDE4A (0.36) | GAAKDM4EKMT2ATDP1NPC1 | |
| SCHEMBL3107258 | 0.80 | HSD17B1 (0.38) | CCNB2CDK1CCNB1CCNB3CYP1A2 | |
| SCHEMBL17687653 | 0.80 | CLK4 (0.38) | DYRK1ACLK4GAANOTUMCCNB2 | |
| SCHEMBL473159 | 0.78 | MAOA (0.32) | — | |
| SCHEMBL9429848 | 0.78 | MAPT (0.36) | GAAKDM4EKMT2ANPC1TP53 | |
| SCHEMBL1275382 | 0.77 | MAOA (0.31) | — | |
| SCHEMBL2950392 | 0.76 | KDM4E (0.36) | GAACCNB2CDK1CCNB1GSK3A | |
| SCHEMBL29148790 | 0.75 | AMY1A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403780-A | Photosensitizer material, preparation method and application thereof in preparation of polymer | 合肥工业大学 | 2022-11-29 | — | — | CN | claimed |
| CN-115403780-B | Photosensitizer material, preparation method and application thereof in preparation of polymer | 合肥工业大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-115403780-A | Photosensitizer material, preparation method and application thereof in preparation of polymer | 合肥工业大学 | 2022-11-29 | — | — | CN | disclosed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| CN-110731961-A | Metal organic framework, pharmaceutical preparation and use thereof in preparing medicament | 芝加哥大学 | 2020-01-31 | — | — | CN | disclosed |
| CN-107001031-B | Metal organic framework, pharmaceutical preparation and application of pharmaceutical preparation in preparation of drugs | 芝加哥大学 | 2019-11-15 | — | — | CN | disclosed |
| CN-107001031-A | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy and any combination thereof | 芝加哥大学 | 2017-08-01 | — | — | CN | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| CN-102325550-A | Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature | QUADRA LOGIC TECH INC | 2012-01-18 | — | — | CN | disclosed |
| CN-101550140-B | Method and apparatus for synthesis of tetaraary porphyrin | UNIV HUNAN | 2011-06-15 | — | — | CN | disclosed |
| US-6599891-B2 | Administering to the subject an amount of a photosensitizer (PS) sufficient to allow said photosensitizer to localize in lesion; irradiating said lesion with light having a wavelength absorbed by said PS | QLT INC. (CA) | 2003-07-29 | — | — | US | disclosed |
| US-20030099596-A1 | Treatment of macular edema | BAUSCH HEALTH IRELAND LIMITED (IE) | 2003-05-29 | — | — | US | disclosed |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-20030083649-A1 | Method for reducing or preventing PDT related inflammation | VALEANT SP. Z.O.O. (PL) | 2003-05-01 | — | — | US | disclosed |
| US-20020183302-A1 | Method to prevent vision loss | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020173832-A1 | Reduced fluence rate PDT | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | BAUSCH HEALTH COMPANIES INC. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099596-A1 | Treatment of macular edema | VEGFA, PPOX, FLT4 | DYRK1A 1517/4885CLK4 93/4885GAA 4269/4885 |
| US-20020183302-A1 | Method to prevent vision loss | VEGFA, ALDH1A2, PDE6C | DYRK1A 3041/4885CLK4 2182/4885GAA 740/4885 |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | LIPA, MLEC, ABCG2 | DYRK1A 4372/4885CLK4 3119/4885GAA 1114/4885 |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | PIN1, PPOX, DHFR | DYRK1A 766/4885CLK4 3540/4885GAA 641/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | DYRK1A 3231/4885CLK4 4368/4885GAA 439/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | DYRK1A 3116/4885CLK4 4305/4885GAA 2503/4885 |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | ALDH1A2, AGER, CRY2 | DYRK1A 2336/4885CLK4 826/4885GAA 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.